Welcome to our dedicated page for Dariohealth news (Ticker: DRIO), a resource for investors and traders seeking the latest updates and insights on Dariohealth stock.
DarioHealth Corp (NASDAQ: DRIO) is a leader in digital therapeutics, revolutionizing chronic condition management through data-driven health solutions. This news hub provides investors and healthcare professionals with essential updates on corporate milestones, clinical validations, and strategic partnerships.
Access timely press releases covering earnings reports, product innovations, and business expansions. Our curated collection includes updates on Dario's integrated platform developments, partnership announcements with healthcare providers, and regulatory milestones in digital health.
Key focus areas include advancements in personalized coaching technologies, behavioral health integrations, and outcomes from clinical studies. Stay informed about DarioHealth's progress in merging life sciences with digital tools to improve chronic care management for employers, payers, and patients.
Bookmark this page for direct access to verified corporate communications. Check regularly for updates on DRIO's market-moving developments in the rapidly evolving digital therapeutics sector.
DarioHealth Corp. (Nasdaq: DRIO) has appointed Eitan Shay as Chief Product Officer and Arnaud Robert as Strategic Advisor to the CEO. These strategic appointments aim to enhance Dario's digital therapeutics platform amidst increasing market demand. Eitan Shay brings extensive experience from Livongo, Teladoc Health, and Meta Platforms. On April 3, 2023, Shay was granted stock options to purchase 100,000 shares at $3.93, alongside performance-based options for an additional 80,000 shares. Dario's innovative solutions empower individuals to manage chronic conditions more effectively, reinforcing the company's commitment to continuous improvement in healthcare delivery.
DarioHealth Corp. (Nasdaq: DRIO) has announced a significant contract with a leading nationwide Pharmacy Benefits Manager (PBM) to provide its digital therapeutics, including a diabetes solution, starting in Q2 2023. This contract marks the first outcome of Dario's strategic partnership with Sanofi and is expected to replace the PBM's existing diabetes solution. The initiative aims to enhance Dario's portfolio in the employer and payer markets, generating revenue growth through 2023. The partnership is a vital step in Dario's strategy to expand its digital health solutions, demonstrating the value of collaborations in the rapidly growing digital therapeutics sector.
DarioHealth Corp. (Nasdaq: DRIO) has entered into a strategic partnership with Amwell (NYSE: AMWL), integrating Dario's cardiometabolic solutions into Amwell's digital care delivery platform, which covers over 90 million lives. This collaboration aims to enhance the care experience for individuals with conditions such as diabetes and hypertension by providing access to Dario's personalized digital health solutions. The Dario cardiometabolic suite will be available to Amwell customers in the second half of 2023, promoting a seamless member journey and supporting better health management.
FAQ
What is the current stock price of Dariohealth (DRIO)?
What is the market cap of Dariohealth (DRIO)?
